Polymer Factory (POLYMER) Q1 2025 earnings summary

Executive summary

• Secured a strategic SpheriCal® order from a global biopharma leader, marking a key milestone for business development and future collaborations.

• Directed share issue completed to increase working capital and strengthen financial position.

• Focused on sales growth, cost optimization, and proactive customer engagement, with cost-reduction measures expected to show results in Q2 2025.

• SpheriCal® product line saw increased global interest, with a substantial order from a major scientific instruments company post-quarter.

• No significant operational impact from global trade tensions or geopolitical developments.

Financial highlights

• Net sales for Q1 2025 were KSEK 348, down 12% year-over-year from KSEK 395.

• Profit (loss) for the period improved by 30% to KSEK -880 from KSEK -1,249 in Q1 2024.

• Basic earnings per share improved to SEK -0.08 from SEK -0.11 year-over-year.

• Cash flow for the period was KSEK 346, compared to KSEK -1,590 in Q1 2024, mainly due to financing activities.

• Cash and bank at period end was KSEK 2,061, down from KSEK 3,049 a year earlier.

Outlook and guidance

• Cost-reduction measures initiated, with tangible results expected in Q2 2025.

• Board notes risk of insufficient financing over the next 12 months if sales do not improve, cost reductions are inadequate, or new capital is not raised.

• Continued focus on growth, innovation, and profitability, leveraging strategic partnerships.